Abstract
Objective. To evaluate the efficacy and safety of anakinra in inpatient management of acute gout and pseudogout. Methods. Hospitalized patients with acute gout (n = 77) or pseudogout (n = 11) or both (n = 3) were analyzed for response to anakinra and adverse effects. Results. Half of all patients had comorbidities limiting the treatment choice. Anakinra was well tolerated, and 92% of gout flares and 79% of pseudogout flares responded to treatment. Conclusion. Anakinra is an effective and safe treatment for acute gout and pseudogout in hospitalized patients, particularly in those with comorbidities.
Original language | English (US) |
---|---|
Pages (from-to) | 748-750 |
Number of pages | 3 |
Journal | Journal of Rheumatology |
Volume | 46 |
Issue number | 7 |
DOIs | |
State | Published - 2019 |
Keywords
- Anakinra
- Gout
- Pseudogout
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology